StockMarketWire.com - Realm Therapeutics said the first patient has been dosed in its Phase 2 study of PR013, a treatment of allergic conjunctivitis.

The study is being conducted in the US and top line data is expected in the 2018 second quarter, the company said.


At 9:12am: [LON:RLM] Realm Therapeutics Plc share price was 0p at 39p



Story provided by StockMarketWire.com